Hyperactivity of the transmembrane adaptor protein STING, which normally helps the cell respond to infection and injury, has been implicated in several autoimmune or inflammatory diseases, including systemic lupus erythematosus and amyotrophic lateral sclerosis.
CD122 – shared beta subunit of the IL-15 and IL-2 receptors, two targets for the figurative price of one – has drawn the eyes of many drug developers, among them Anaptysbio Inc., which will roll out phase Ib results in celiac disease during the fourth quarter of this year with ANB-033. The San Diego-based firm intends to weigh the candidate in a second inflammatory disease. Under consideration is eosinophilic esophagitis, an indication that has itself proven widely intriguing.
As China emerges as a critical commercial market and a source of global innovation, the newly released 2026 edition of Clarivate’s Drugs to Watch report highlights six drugs to watch in the China market for the year ahead.
